IL202002A0 - Method of treating diabetes - Google Patents

Method of treating diabetes

Info

Publication number: IL202002A0
Authority: IL; Israel
Prior art keywords: treating diabetes; diabetes; treating
Prior art date: 2007-05-31

Application number

IL202002A

Original Assignee

Gilead Palo Alto Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-31

Filing date

2009-11-09

Publication date

2010-06-16

2009-11-09 Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc

2010-06-16 Publication of IL202002A0 publication Critical patent/IL202002A0/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL202002A 2007-05-31 2009-11-09 Method of treating diabetes IL202002A0 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2007/070140 WO2008147417A1 (en)	2007-05-31	2007-05-31	Method of treating diabetes

Publications (1)

Publication Number	Publication Date
IL202002A0 true IL202002A0 (en)	2010-06-16

Family

ID=38812044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL202002A IL202002A0 (en)	2007-05-31	2009-11-09	Method of treating diabetes

Country Status (11)

Country	Link
EP (1)	EP2152268A1 (en)
JP (1)	JP2010528112A (en)
KR (1)	KR20100038322A (en)
CN (1)	CN101678017A (en)
AU (1)	AU2007354300A1 (en)
BR (1)	BRPI0721741A2 (en)
CA (1)	CA2687381A1 (en)
IL (1)	IL202002A0 (en)
MX (1)	MX2009012957A (en)
NO (1)	NO20093592L (en)
WO (1)	WO2008147417A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003099281A2 (en)	2002-05-21	2003-12-04	Cv Therapeutics, Inc.	Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
US8822473B2 (en)	2002-05-21	2014-09-02	Gilead Sciences, Inc.	Method of treating diabetes
US20090111826A1 (en) *	2007-02-13	2009-04-30	Louis Lange	Use of ranolazine for the treatment of cardiovascular diseases
RU2691620C1 (en) *	2018-11-26	2019-06-14	Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России)	Method for prediction of the risk of developing ischemic heart disease in patients with type 2 diabetes mellitus combined with subclinical thyrotoxicosis
CN110812344A (en) *	2019-12-17	2020-02-21	卓和药业集团有限公司	Pharmaceutical composition for treating diabetes complicated with angina pectoris and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6479496B1 (en) *	1998-09-10	2002-11-12	Cv Therapeutics, Inc.	Methods for treating angina with ranolazine
WO2003099281A2 (en) *	2002-05-21	2003-12-04	Cv Therapeutics, Inc.	Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
GEP20094784B (en) *	2005-01-06	2009-09-25	Cv Therapeutics Inc	Sustained release pharmaceutical formulations

2007
- 2007-05-31 AU AU2007354300A patent/AU2007354300A1/en not_active Abandoned
- 2007-05-31 WO PCT/US2007/070140 patent/WO2008147417A1/en not_active Ceased
- 2007-05-31 JP JP2010510275A patent/JP2010528112A/en active Pending
- 2007-05-31 MX MX2009012957A patent/MX2009012957A/en not_active Application Discontinuation
- 2007-05-31 EP EP07797962A patent/EP2152268A1/en not_active Withdrawn
- 2007-05-31 BR BRPI0721741-2A patent/BRPI0721741A2/en not_active IP Right Cessation
- 2007-05-31 KR KR1020097027359A patent/KR20100038322A/en not_active Ceased
- 2007-05-31 CN CN200780053142A patent/CN101678017A/en active Pending
- 2007-05-31 CA CA002687381A patent/CA2687381A1/en not_active Abandoned
2009
- 2009-11-09 IL IL202002A patent/IL202002A0/en unknown
- 2009-12-23 NO NO20093592A patent/NO20093592L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2008147417A1 (en)	2008-12-04
EP2152268A1 (en)	2010-02-17
AU2007354300A1 (en)	2008-12-04
BRPI0721741A2 (en)	2013-02-13
CN101678017A (en)	2010-03-24
CA2687381A1 (en)	2008-12-04
NO20093592L (en)	2010-01-20
MX2009012957A (en)	2010-03-03
KR20100038322A (en)	2010-04-14
JP2010528112A (en)	2010-08-19

Publication	Publication Date	Title
IL212348A0 (en)	2011-06-30	Treatment method
EP2032131A4 (en)	2009-09-02	Method of treatment
ZA201006367B (en)	2011-05-25	Oxadiazoanthracene compounds for the treatment of diabetes
SG10201601056XA (en)	2016-04-28	Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
ZA201006648B (en)	2011-07-27	Methods of treatment
PL2441462T3 (en)	2020-01-31	Method for treating type I diabetes
IL200769A (en)	2015-09-24	Method of treating potash
GB0718684D0 (en)	2007-10-31	Treatment method
EP2144886A4 (en)	2012-10-03	Method of treating melanoma
GB0610746D0 (en)	2006-07-12	Method of treatment
IL202002A0 (en)	2010-06-16	Method of treating diabetes
EP2164494A4 (en)	2010-06-02	Methods of treatment
EP2498794A4 (en)	2014-04-09	Method of treatment of type 2 diabetes
ZA201007680B (en)	2011-09-28	Method of treating metalliferrous materials
EP2203432A4 (en)	2011-04-27	Method of treatment
HK1141223A (en)	2010-11-05	Method of treating diabetes
GB0717337D0 (en)	2007-10-17	Method of treatment
ZA200907778B (en)	2010-06-30	Method of treating diabetes
GB0823435D0 (en)	2009-01-28	Method of treatment
GB0618227D0 (en)	2006-10-25	Novel method of treatment
ZA201102198B (en)	2012-06-27	Treatment method
GB0802903D0 (en)	2008-03-26	Treatment of diabetes
GB0711228D0 (en)	2007-07-18	Treatment method
AU2006906499A0 (en)	2006-12-07	Method of treating diabetes
AU2008902659A0 (en)	2008-06-12	Method of Treatment